Bio-Rad Laboratories, Qiagen Mull Merger Of Equals
Bio-Rad Laboratories Inc (NYSE: BIO) is reportedly in talks to merge with Qiagen NV (NYSE: QGEN), but any agreement isn't likely for another few weeks or more, or it may not happen at all.
Sanofi – Regeneron Tout Additional Positive Data From Flagship Dupixent Product
Sanofi SA (NASDAQ:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) presented more positive data for their Dupixent product. The companies said new Dupixent data showed…
Exxon Mobil Shows Initial Interest In Denbury Takeover
Exxon Mobil Corp (NYSE: XOM) has expressed preliminary interest in Denbury Inc (NYSE: DEN). No final decision has been made, and Exxon could opt against proceeding with a potential deal.
French Petrol Stations Strike Continues As Union Rejects Wage Talk ‘Blackmail’
Workers striking at TotalEnergies SE (NYSE:TTE) and Exxon Mobil Corp’s (NYSE:XOM) French refineries have rejected a pay offer, extending the strike that…
Despite Advancement, Benefits From Alzheimer’s Drugs May Be Limited, Say Researchers
Recently, Biogen Inc (NASDAQ:BIIB) and Eisai Co (OTC: ESALY) announced encouraging data from the most-watched Alzheimer’s therapies in the clinic. Lecanemab cleared accumulations…
Janssen Touts Encouraging Data From Two Ulcerative Colitis Treatments
Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE:JNJ), announced data from an ongoing analysis of a Phase 2a trial of guselkumab…
Centre Piece Of Merck’s $11.5B Acceleron Buyout Aces Late-Stage Cardiovascular Trial
Merck & Co Inc (NYSE:MRK) announced topline results from the pivotal Phase 3 STELLAR trial evaluating the safety and…
Iradimed Withdraws FDA Application For Updated MR IV Pump System
Iradimed Corporation (NASDAQ:IRMD) voluntarily withdrew its 510(K) application for its next-generation MRidium 3870 Infusion Pump System. Roger Susi, President and Chief…
Applied DNA Sciences Stock Surges On largest LinearDNA Contract
Applied DNA Sciences Inc (NASDAQ:APDN) received its largest single purchase order for LinearDNA valued above the mid-six figures. The order was…
FDA Rejects Supernus Pharma’s Minimally Invasive Parkinson’s Therapy
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) received FDA’s complete response letter (CRL) for the SPN-830 marketing application. SPN-830 is an investigational apomorphine infusion…